Title (verbatim)
The shift from intravenous infusion to subcutaneous injection changes what a peptide program has to solve, and almost none of those changes are clinical. They are manufacturing and formulation problems: a subcutaneous dose has to fit into roughly 1 to 2 mL of injected volume, which means the concentration has to rise, and every downstream property of the molecule responds to that rise. This guide works through the six decisions that follow from it, in the order a development team actually meets them.
The framing is deliberately narrow. This is not a review of subcutaneous delivery as a therapeutic strategy, and it makes no claim about clinical outcomes for any peptide. It is a map of the chemistry and process questions that a route-of-administration change pushes onto the manufacturing side, written for the people who have to answer them: formulation and process development leads, CMC managers, and technical evaluators assessing whether a supplier can engage these problems before a tech-transfer package is frozen.
Six dimensions drive the analysis, and they are chained rather than parallel. Concentration sets the ceiling on dose per injection. Solubility determines whether that concentration is reachable at all. Aggregation and viscosity are the two failure modes that appear once it is. Formulation compatibility decides what excipients and pH you can use to manage them. Stability testing is how you find out whether the resulting system survives long enough to be worth manufacturing. Each decision constrains the next, which is why treating them as six independent workstreams tends to produce a formulation that passes every individual test and still cannot be filled.
The guide closes with a decision framework you can apply to a specific molecule, a set of evaluation criteria for supplier conversations, and the questions worth asking before you commit to a concentration target. Where a claim depends on published data, the source is linked in the sentence that makes it. Where the honest answer is “this depends on your molecule,” the guide says so rather than inventing a threshold.
Key Takeaways
Jasa A subcutaneous route pushes peptide programs toward high-concentration formulation, where solubility, aggregation, viscosity and stability stop being separate problems and start constraining each other.
The practical ceiling on peptide concentration is usually set by viscosity and syringeability rather than by solubility alone, so a solubility screen on its own will not tell you whether a target concentration is manufacturable.
Formulation compatibility decisions (pH, buffer, excipients, counterions) made early determine which stability-indicating methods you will need later, so analytical planning belongs in pre-formulation, not after it.
Supplier evaluation should test whether a partner can discuss cross-disciplinary trade-offs, chemistry against biology against process, rather than whether they can list capabilities.
Why the route change lands on manufacturing
A peptide that was designed, characterised and manufactured for IV administration arrives at a subcutaneous program with a set of properties that were never constraints. IV delivery tolerates dilute solutions, large volumes and short in-use stability windows, because the dose goes directly into the bloodstream and the formulation is often prepared close to the point of use. Subcutaneous delivery removes all three allowances at once.
The injected volume is the binding constraint. Subcutaneous tissue tolerates a limited volume per injection site, and while the exact limit depends on the site, the patient and the formulation, the practical consequence for development is the same: to deliver the same mass of peptide in a smaller volume, concentration has to increase, often by an order of magnitude or more. That single requirement propagates through the entire process.
It also changes the economics of the molecule. A higher concentration means more peptide per batch volume, which changes the cost structure of solid-phase synthesis and purification, the volume of solvent and buffer consumed, and the burden on the analytical methods that have to demonstrate identity, purity and potency at the new concentration. A process that was validated at low concentration is not automatically valid at high concentration, and the difference is not a linear scale-up.
The third consequence is less obvious and more expensive to discover late: the properties that govern whether a high-concentration peptide solution is usable are not the properties that govern its purity. A peptide can be 98% pure by HPLC and still be unmanufacturable as a subcutaneous product, because purity says nothing about whether the solution can pass through a 27-gauge needle or survive twelve months at 2 to 8 °C. Development teams that inherit a purity-focused release specification often find that the specification does not describe the product they now need to make.
Concentration: the decision that sets every other constraint
The target concentration is the first number a subcutaneous program has to fix, and it is usually set by dose and injection volume rather than by what the molecule can tolerate. That inversion is the source of most of the difficulty. In an IV program, concentration is an output of the formulation work. In a subcutaneous program, it is an input that the formulation work has to satisfy.
Working backwards from dose and volume gives a target, and the target is often uncomfortable. If a peptide needs a 100 mg dose and the injection volume is capped at 1 mL, the formulation has to deliver 100 mg/mL. Whether that is achievable depends on the molecule, and the honest answer for many peptides is that it is achievable only with formulation intervention, or not at all without changing the dose, the dosing frequency or the device.
Two practical points follow. First, the concentration target should be treated as a hypothesis to be tested in pre-formulation, not as a specification handed to the formulation team. Testing it early, with a small amount of material and a solubility screen that goes above the target rather than stopping at it, is far cheaper than discovering the ceiling during process development. Second, the target should be set with the device in mind. A prefilled syringe, an autoinjector and a vial-and-syringe presentation impose different constraints on volume, viscosity and container compatibility, and choosing the presentation after the formulation is fixed removes most of the available design space.
There is also a manufacturing consequence that is easy to defer and expensive to defer too long. High-concentration peptide solutions are harder to filter, harder to fill accurately, and harder to hold without losses to surfaces and tubing. Those are process problems, but they are decided by formulation choices, which is why the two workstreams cannot be sequenced one after the other.
Solubility: whether the target concentration is reachable
Solubility is the first hard gate. If the peptide will not dissolve to the target concentration in a physiologically acceptable vehicle, no amount of downstream optimisation will produce a subcutaneous product, and the program has to change the molecule, the concentration target or the route.
Peptide solubility is governed by the same balance that governs protein solubility: the distribution of hydrophobic and hydrophilic residues, the net charge at the formulation pH, and the ionic strength of the vehicle. For peptides, the sequence matters more than the aggregate properties, because a short sequence with a hydrophobic stretch will behave differently from a longer sequence with the same overall hydrophobicity. This is where the chemistry and the biology of the program have to be discussed together, and it is a common point of failure in supplier conversations: a synthesis-focused partner may be able to make the peptide but not to advise on whether the sequence is compatible with the concentration target.
The practical work in pre-formulation is a pH-solubility profile across a range wide enough to find the actual minimum and maximum, not a single-point measurement at a default pH. Peptides often show a pronounced solubility minimum near the isoelectric point and much higher solubility away from it, so a single measurement can be misleading in either direction. Counterion selection matters too: the salt form of a peptide can change its solubility substantially, and the counterion that works for a lyophilised IV product is not necessarily the one that works for a concentrated solution.
Two limitations are worth stating plainly. Solubility measured in a simple buffer is not solubility in the final formulation, because excipients, preservatives and tonicity agents all shift the equilibrium. And solubility measured at room temperature is not solubility at the storage temperature, which is the condition that actually governs whether the product precipitates on stability. A solubility screen is a screening tool, not a release specification, and it should be designed to eliminate options rather than to confirm a choice.
Aggregation and viscosity: the two failure modes that appear at high concentration
Once the target concentration is reachable, two properties decide whether the resulting solution is usable, and they tend to move in opposite directions. Aggregation is a chemical and physical stability problem. Viscosity is a manufacturing and administration problem. Managing one often worsens the other, which is why high-concentration peptide formulation is a trade-off exercise rather than an optimisation.
Aggregation in peptides takes several forms: self-association into dimers and higher oligomers, fibril formation driven by hydrophobic sequence segments, and interfacial aggregation at air-liquid and container surfaces. The last of these is particularly relevant to subcutaneous products, because the manufacturing process involves pumping, filtration and filling steps that generate interfaces, and because the final container is a small volume with a high surface-to-volume ratio. Aggregation matters for two reasons: it can reduce the effective dose, and it can create immunogenicity risk. Neither is a claim about clinical outcomes for a specific product; both are reasons the property has to be characterised and controlled.
Viscosity is the constraint that most often kills a high-concentration peptide formulation, because it is a function of concentration in a strongly non-linear way. As concentration rises, peptide molecules interact more, and the solution can become too viscous to pass through a fine-gauge needle within a reasonable injection time, or too viscous to filter and fill with the accuracy the process requires. The threshold is device-dependent: an autoinjector with a defined spring force tolerates a different viscosity than a manual syringe, and a subcutaneous infusion pump tolerates more than either.
The interaction between the two is the part that catches teams out. Formulation strategies that reduce aggregation, such as adding a surfactant or adjusting ionic strength, can increase viscosity. Strategies that reduce viscosity, such as adding an excipient that disrupts self-association or lowering the concentration, can increase aggregation risk. There is no formulation that minimises both, so the work is to find an acceptable region rather than an optimum, and to define that region with the device and the storage condition in view.
Formulation compatibility: what you can and cannot put in the vial
Formulation compatibility is where the earlier decisions become concrete, because it determines which excipients, buffers, pH values and counterions are available to solve the solubility, aggregation and viscosity problems.
The constraint set is broader than it first appears. Every component has to be acceptable for subcutaneous administration at the concentration used, compatible with the peptide over the shelf life, compatible with the container and closure system, and compatible with the manufacturing process. A buffer that holds pH perfectly in a dilute IV solution may fail to hold it at high concentration, where the peptide itself contributes significantly to the buffering capacity. A preservative that is acceptable in a multi-dose vial may be incompatible with the peptide or with the device. A tonicity agent chosen for a dilute solution may need to change when the peptide concentration rises.
This is also where the analytical plan has to be decided, because the formulation determines which degradation pathways are possible and therefore which methods are stability-indicating. A formulation at pH 5 with a specific counterion will produce a different impurity profile from the same peptide at pH 7, and a method developed for one will not necessarily detect the relevant degradants in the other. Building the analytical method set after the formulation is fixed is a common and costly sequencing error.
The practical approach is to define the compatibility space early, as a set of constraints rather than a single formulation: an acceptable pH window, a list of excipients that are compatible with the peptide and the route, and the container and closure options that have been tested. That space then constrains the solubility, aggregation and viscosity work instead of being discovered at the end of it.
Stability testing: how you find out whether the system holds
Stability testing is the last of the six decisions in sequence and the one that determines whether the earlier five produced something manufacturable. It is also the decision Shop most often under-scoped, because the stability program for a concentrated subcutaneous peptide is not the same as the stability program for a dilute IV solution.
The design questions are specific. What are the storage conditions, and do they include a frozen or refrigerated state, a room-temperature in-use period, and the temperature excursions that distribution will produce? What are the relevant degradation pathways for this sequence at this pH, and are the analytical methods sensitive enough to quantify them at the concentrations involved? What is the container-closure system, and does the stability program test the product in the container it will actually be filled into? What is the in-use stability after the patient opens the device or the vial, which for a subcutaneous product may be a longer and more variable period than for an IV product prepared at the point of use?
For peptides specifically, the aggregation question makes stability testing more than a purity exercise. A stability-indicating method set for a concentrated peptide has to be able to detect and quantify soluble aggregates and sub-visible particles, not just the main peak and its chemical degradants. That requirement should be established during method development, not added when a stability timepoint shows an unexpected result. Ngeunaan
The regulatory frame for this work is well established, and the relevant guidance is public. The ICH Q1 stability testing guidelines set out the core expectations for drug substance and drug product, and the ICH Q6B specifications for biotechnological and biological products address the test methods and acceptance criteria appropriate to peptides and related products. Teams working on a subcutaneous peptide should read both against their specific molecule rather than treating either as a checklist, because the guidance defines what has to be demonstrated, not what the answer will be.
A decision framework you can apply to a specific molecule
The six dimensions are easier to work with as a sequence of gates than as a list of topics. Applied to a specific peptide, the framework runs like this.
Gate 1: Is the target concentration reachable? Run a pH-solubility profile above and below the target, across a wide enough pH range to find the minimum and maximum, with the intended counterion. If the target is not reachable, stop and revisit the dose, the volume or the molecule before doing anything else.
Gate 2: Is the resulting solution usable? Measure viscosity at the target concentration and compare it against the injection time and device constraints, not against a generic threshold. Assess aggregation at the same concentration, including after the shear and interfacial exposure the process will produce.
Gate 3: Can the trade-offs be managed within the compatibility space? Identify the excipients, pH and counterion options that are acceptable for subcutaneous administration and compatible with the peptide, then test whether any combination moves viscosity and aggregation into an acceptable region together.
Gate 4: Does the system hold? Design the stability program around the degradation pathways the formulation makes possible, in the container the product will be filled into, with methods that can quantify aggregates as well as chemical degradants.
Gate 5: Can it be made at scale? Confirm that the process steps the formulation requires, including filtration, filling and holding, work at the target concentration and the intended batch size.
The gates are ordered because each one can eliminate options that the next one depends on. Running them out of order, or in parallel without acknowledging the dependencies, is how programs end up with a formulation that satisfies every individual specification and still cannot be manufactured.
What to look for in a manufacturing partner
The evaluation criteria for a supplier follow from the framework, and they are mostly about whether the partner can engage the trade-offs rather than whether they can perform a list of unit operations.
The first criterion is cross-disciplinary fluency. A subcutaneous peptide program requires someone who can discuss sequence chemistry, solution behaviour and process constraints in the same conversation, because the decisions are coupled. A partner who can only discuss synthesis, or only discuss analytical testing, will hand the coupling problem back to you.
Sintésis péptida The second is pre-formulation engagement. The most expensive mistakes in this space are made before the formulation is fixed, and a partner who can only start work once a formulation is specified is structurally unable to prevent them. Ask what the partner needs in order to give a view on whether a target concentration is realistic for a given sequence, and how early in the program they can provide it.
The third is analytical depth at high concentration. Confirm that the partner’s methods can quantify aggregates and sub-visible particles, not just purity by HPLC, and that they can develop methods against a formulation rather than only against a reference standard.
The fourth is scalability honesty. Ask what changes between milligram and kilogram scale at the target concentration, and expect a specific answer about filtration, mixing, hold times and fill accuracy rather than a general assurance. An integrated chemistry and biology organisation with solid-phase synthesis, microbial fermentation and large-scale production capability, such as MOL Changes, is one example of a partner structured to engage these questions early, though the criteria above are what matter in the evaluation, not the capability list.
The fifth is documentation. Tech transfer, method transfer and batch records are where the coupled decisions either get preserved or get lost. Ask to see how a formulation rationale is documented, and whether the analytical methods travel with it.
Questions to settle before you commit to a concentration target
The concentration target is the decision that constrains everything else, and it is usually set earlier than the information needed to set it well. These are the questions worth answering first.
What is the maximum injection volume the device and the patient population will accept, and how much margin does that leave? Which presentation is intended, and does the viscosity budget reflect that device rather than a generic syringe? Has the solubility screen gone above the target concentration, or only up to it? Has aggregation been assessed under the process conditions, including shear and interfacial exposure, or only at rest? Which degradation pathways does the proposed formulation make possible, and can the current methods quantify them? What is the in-use stability requirement, and does it match the presentation? And what changes at scale, specifically, when the process runs at the target concentration rather than at a development concentration?
Answering these before the target is fixed is cheaper than answering them afterwards. Where the answer is unknown, the honest move is to run the experiment rather than to assume the target is achievable, because the cost of the assumption compounds through every subsequent decision in the program.
Scope instruction (verbatim)
This article focuses on subcutaneous peptide manufacturing and the formulation decisions that determine whether a subcutaneous peptide program is technically viable. It covers six dimensions in early process development: concentration, solubility, aggregation, viscosity, formulation compatibility, and stability testing. It does not cover device selection, regulatory filing strategy, or clinical trial design except where those topics directly constrain a formulation decision.
The six dimensions are not independent workstreams. They are a chain, and each link constrains the next. Concentration sets the dose volume the device must deliver. Solubility determines whether that concentration is reachable in an aqueous vehicle at all. Aggregation Péptida sintétik and viscosity are the two failure modes that appear once concentration rises. Formulation compatibility decides which excipients can be used to manage them. Stability testing is how you find out whether the answer holds for the shelf life you need.
One framing sentence is worth carrying through the rest of this guide: think of a subcutaneous peptide formulation as a saturated solution that has to stay saturated, stay fluid, and stay intact, all at once, for two years. Every decision below is a trade against one of those three requirements.
Why the chain matters more than any single dimension
Most subcutaneous peptide programs that stall do not stall because one dimension was handled badly in isolation. They stall because a decision made early, usually at the concentration target, forecloses an option that would have been available later. Set a 100 mg/mL target before you understand the solubility profile at your chosen pH, and you may spend months trying to formulate your way out of a constraint that a different buffer system would have avoided entirely.
The practical consequence is that early process development for a subcutaneous peptide should be sequenced, not parallelized. Concentration and solubility are decided first because they define the feasible design space. Aggregation and viscosity are characterized next because they determine whether that space is practically usable. Formulation compatibility and stability testing come last because they validate the specific composition you have chosen, not the space around it.
The six dimensions and what each one decides
Concentration sets the dose volume, and the dose volume sets the device class. Conventional prefilled syringes and autoinjectors are typically limited to roughly 1 to 2.5 mL per dose, and devices that enable more than 5 mL have been central to expanding subcutaneous use. High-dose biologics run into volume limits alongside high-concentration stability and viscosity, aggregation, and particulate bottlenecks, with some subcutaneous programs targeting 10 to 20 mL (PMC7812053, 2021). For a peptide, the concentration target is therefore a device-constrained number, not a free variable, and it should be set with the volume ceiling in view from the start. The route shift itself is driven by a recognizable set of pressures: subcutaneous delivery reduces infusion-center burden and supports home administration and lifecycle management (Roots Analysis report, 2018, updated 2025). One caution on the numbers that circulate in this space: the widely repeated figure of more than 340 subcutaneous biologics in development is a product count from a commercial market report, not a share of the biologics pipeline, and it should not be cited as one.
Solubility decides whether the concentration target is reachable in an aqueous vehicle. Peptide aqueous solubility is at a minimum at the peptide’s isoelectric point, where net charge is zero, and moving the pH away from the pI can vastly improve solubility (AAPS J review, 2015). This is the single most useful lever in early peptide formulation work, and it is also the one most often fixed prematurely, because the buffer system chosen for stability reasons may sit close to the pI for solubility reasons.
Aggregation decides whether the formulation survives its own concentration. Peptide aggregation and fibrillation proceed through a recognizable sequence: monomer self-association, transient oligomers, nucleation, then templated fibril elongation, commonly with a lag phase, a growth phase, and a plateau, and some systems add secondary nucleation or fragmentation on top of that (peptide aggregation review, 2017). The lag phase is the part that matters commercially, because a formulation can look clean at release and fail months later when the lag phase ends. Detecting that failure requires matching the analytical method to the measurand: ThT fluorescence detects cross-β amyloid fibrils, SEC separates by apparent hydrodynamic size, DLS reports a hydrodynamic size distribution with a bias toward larger scatterers, AUC measures sedimentation without a stationary phase, CD reports secondary-structure change, and FTIR reports amide I and β-sheet vibrational signatures and suits turbid samples (aggregation-method literature, 2014). No single method covers the pathway, which is why the panel is a design decision. Produksi péptida
Viscosity decides whether the formulation is injectable at all. Protein viscosity rises exponentially rather than linearly above a threshold concentration, so viscosity becomes the limiting factor steeply rather than gradually (viscosity review, 2018). That exponential behavior is why viscosity problems tend to appear suddenly during a concentration increase rather than degrading smoothly, and why the syringeability check belongs early rather than at the end of development. The magnitude is not subtle: an IgG1 monoclonal antibody at 130 mg/mL under low ionic strength measured 120 cP, and viscosity fell to 20 cP once 150 mM NaCl was added, an effect attributed to electrostatic multipoint attractions between molecules (viscosity review, 2018). Ionic strength is therefore a formulation variable in its own right, not just a buffer detail.
Formulation compatibility decides which excipients are available to manage the first four dimensions. This is where peptide formulation development diverges most sharply from monoclonal antibody work. Peptide formulation problems are dominated by biochemical fragility, meaning proteolysis, short half-life, and membrane permeability, while mAb formulation problems are dominated by colloidal stability, high-concentration viscosity, and aggregation (comparative formulation review, 2026). Excipient strategies borrowed from mAb platforms often address the wrong failure mode for a peptide. The same divergence shows up downstream in filtration, where the protein load itself drives performance: in one membrane study, sterile filtration flux declined over the first 10 minutes by 4.9%, 6.4%, and 28.0% for a hydrophilic PVDF 0.3 µm filter and by 12.2%, 17.1%, and 76.6% for a PES 0.26 µm filter at 1, 2, and 5 g/L bovine serum albumin respectively, with both filters declining more than 60% within 20 minutes at the highest load (Membranes research article, 2022). Protein adsorption to the same membranes rose with feed concentration, from 66.6 to 152.2 µg/cm² for the PVDF filter and from 80.7 to 263.2 µg/cm² for the PES filter across the same 1 to 5 g/L range (Membranes research article, 2022). A formulation that is compatible on paper can still lose yield at the sterile filter.
Stability testing decides whether the composition you chose is the composition you can release. It is also where the analytical method set has to be matched to the specific degradation route you are trying to detect, which is a design decision rather than a routine panel selection.
How the dimensions interact in practice
Two interactions are worth naming explicitly, because they are the ones that most often surprise teams new to peptides.
The first is the solubility and viscosity tension. Moving pH away from the pI improves solubility, which supports a higher concentration, but higher concentration is exactly what pushes viscosity up the exponential curve. A pH shift that solves a solubility problem can create an injectability problem, and the two have to be optimized together rather than sequentially.
The second is the aggregation and stability-testing interaction. Because peptide fibrillation has a lag phase, a short accelerated stability study can return a clean result on a formulation that will fail at 18 months. The analytical method set has to be sensitive to the specific aggregation pathway in play, and the study duration has to be long enough to cross the lag phase, or the result is not informative.
What this guide does not cover
Device selection, regulatory filing strategy, and clinical trial design are out of scope except where they constrain a formulation decision. Where a regulatory consideration does bear directly on formulation, such as the fact that a route-of-administration change is generally treated as a new product presentation rather than a simple line extension, with a 351(a) BLA for biologics or a 505(b)(2) for drugs and peptides relying on prior findings in the US, and a possible hybrid approach at the EMA when the route differs from the reference product (NIH Regulatory Knowledge Guide, 2024), it is noted at the point where it affects a formulation choice. It is not developed as a filing-strategy topic here.
The remainder of this guide works through the six dimensions in the order they should be decided, with the decision criteria, the thresholds that matter, and the analytical evidence each one requires.
